SAN DIEGO—(BUSINESS WIRE)—Aug. 24, 2016—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system (CNS)disorders, today announced the appointment of Todd S. Young as ExecutiveVice President, Chief Financial Officer, effective August 22, 2016. Mr.Young reports to Steve Davis, ACADIA’s President and Chief ExecutiveOfficer.
This Smart News Release features multimedia. View the full release here:http://www.businesswire.com/news/home/20160824005294/en/
Todd S. Young, Executive Vice President, Chief Financial Officer of ACADIA Pharmaceuticals (Photo: Business Wire)
“Todd is a seasoned leader with significant financial and operationalexperience in the biopharmaceutical industry,” said Steve Davis. “Hisproven finance and leadership skills will be key as we bring NUPLAZID™(pimavanserin) to patients in need, seek to maximize the significantopportunities ahead for pimavanserin, and deliver on our vision ofbuilding a leading CNS company. We welcome Todd to our team and lookforward to his contributions.”
Mr. Young joins ACADIA from Baxalta Incorporated, where he served asSenior Vice President and Treasurer and played an integral role as abusiness leader and in creating the initial capital structure ofBaxalta. Baxalta was acquired by Shire in June 2016. Prior to theacquisition, Baxalta was a global biopharmaceutical company with $6billion in revenue that was formed in July 2015 when BaxterInternational Inc. spun-out its biopharmaceutical division. Prior toBaxalta, Mr. Young worked for over 14 years at Baxter holding multipleleadership roles, including Corporate Vice President and Treasurer, VicePresident, International Finance, and Vice President, Global FinancialPlanning and Analysis (FP&A). Mr. Young’s global FP&A team wasresponsible for driving Baxter’s budgeting, forecasting, and long-rangefinancial planning. As finance leader for Baxter’s internationaloperations, he led a team of 900 finance members and helped drivebusiness results and strategic decision making for the company’s $8billion international commercial operations.
Early in his career, Mr. Young practiced as a tax attorney at a majorlaw firm. Mr. Young earned his Bachelor of Arts degree in Economics fromGrinnell College and his Juris Doctor from the University of MichiganSchool of Law.
“I am thrilled to join ACADIA,” said Todd Young. “With the recentcommercial launch of NUPLAZID, the company has entered an exciting newphase. I look forward to executing on ACADIA’s growth strategy andbuilding long-term value for shareholders.”
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to ACADIA’s plans to bring NUPLAZID™(pimavanserin) to patients in need, to maximize opportunities forpimavanserin, and to build a leading CNS company and shareholder value,as well as potential contributions of Mr. Young as ACADIA’s ExecutiveVice President, Chief Financial Officer. These statements are onlypredictions based on current information and expectations and involve anumber of risks and uncertainties. Actual events or results may differmaterially from those projected in any of such statements due to variousfactors, including the risks and uncertainties inherent in drugdiscovery, development, approval and commercialization, and incollaborations with others, and the fact that past results of clinicaltrials may not be indicative of future trial results. For a discussionof these and other factors, please refer to ACADIA’s annual report onForm 10-K for the year ended December 31, 2015 as well as ACADIA’ssubsequent filings with the Securities and Exchange Commission. You arecautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date hereof. This caution is madeunder the safe harbor provisions of the Private Securities LitigationReform Act of 1995. All forward-looking statements are qualified intheir entirety by this cautionary statement and ACADIA undertakes noobligation to revise or update this press release to reflect events orcircumstances after the date hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
Investor Contact:
ACADIA Pharmaceuticals Inc.
LisaBarthelemy, Investor Relations
(858) 558-2871
ir@acadia-pharm.com
or
MediaContact:
Taft and Partners
Ted Deutsch
(609)578-8765
ted@taftandpartners.com